Table 2.

Disease activity at enrollment for patients with multidomain vs single-domain PsA disease presentations.

CharacteristicaAll Patients With PsA, N = 2315Biologic Initiators, N = 334
Single Domainb, n = 617Multidomain, n = 1698Single Domainb, n = 45Multidomain, n = 289
Enthesitis, n (%)11 (1.8)528 (31.1)2 (4.4)113 (39.1)
      SPARCC Enthesitis Index (1–16)2.1 (1.5) [11]3.8 (2.9) [528]1.5 (0.7) [2]3.6 (3.0) [113]
Dactylitis, n (%)7 (1.1)228 (13.4)1 (2.2)69 (23.9)
      Dactylitis count (1–20)1.3 (0.5) [7]2.4 (2.1) [228]2.0 (NA) [1]2.5 (1.9) [69]
Tender joint count (1–68)5.7 (6.9) [155]8.7 (10.2) [1226]6.8 (7.4) [20]9.1 (9.5) [240]
Swollen joint count (1–66)4.0 (4.0) [127]4.8 (4.9) [966]4.5 (4.5) [18]6.2 (5.4) [199]
Nail psoriasis VAS (1–100)13.3 (18.8) [67]19.1 (22.5) [975]26.0 (33.9) [2]27.3 (26.2) [157]
DAPSA11.6 (10.1) [337]22.3 (17.5) [950]16.8 (13.0) [31]26.8 (19.2) [189]
DAPSA group, n (%)n = 337n = 950n = 31n = 189
      Remission79 (23.4)53 (5.6)3 (9.7)6 (3.2)
      Low165 (49.0)292 (30.7)15 (48.4)44 (23.3)
      Moderate69 (20.5)359 (37.8)9 (29.0)69 (36.5)
      High24 (7.1)246 (25.9)4 (12.9)70 (37.0)
PASDAS2.8 (1.2) [325]4.1 (1.4) [923]3.7 (1.0) [32]4.7 (1.4) [185]
PASDAS group, n (%)n = 325n = 923n = 32n = 185
      Inactive198 (60.9)258 (28.0)9 (28.1)27 (14.6)
      Moderate80 (24.6)215 (23.3)12 (37.5)33 (17.8)
      Active45 (13.8)375 (40.6)10 (31.3)98 (53.0)
      Very active2 (0.6)75 (8.1)1 (3.1)27 (14.6)
PGA (VAS 0–100)10.9 (15.0) [612]24.3 (21.4) [1686]22.6 (19.4) [45]36.4 (21.5) [287]
PGA of psoriasis (VAS 0–100)12.9 (15.0) [594]28.0 (22.6) [1661]24.9 (20.6) [42]41.6 (22.0) [284]
  • a All values were calculated based on available data and are presented as mean (SD) [n] unless otherwise stated; [n] represents the number of patients with data available.

  • b Single-domain disease presentations for PsA overall (N = 617) included skin disease (53.8%), peripheral arthritis (29.0%), nail psoriasis (10.9%), axial disease (3.4%), enthesitis (1.8%), and dactylitis (1.1%). Single-domain disease presentations for biologic initiators (N = 45) included peripheral arthritis (46.7%), skin disease (35.6%), axial disease (6.7%), nail psoriasis (4.4%), enthesitis (4.4%), and dactylitis (2.2%). DAPSA: Disease Activity in PSoriatic Arthritis; NA: not available; PASDAS: Psoriatic Arthritis Disease Activity Score; PGA: physician global assessment; PsA: psoriatic arthritis; SPARCC: Spondyloarthritis Research Consortium of Canada; VAS: visual analog scale.